IFNA1 and systemic lupus erythematosus: In clinical trials, metformin has been studied in individuals with mild to moderate systemic lupus erythematosus (SLE), and it has been reported to reduce disease relapse, potentially by reducing NET formation and IFNα production by plasmacytoid dendritic cells (36).